Lazard Asset Management
AVIR icon

Lazard Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Lazard Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,298
Closed -$6K – 2249
2023
Q3 		$6K Sell
2,298
-2,953
-56% -$10K ﹤0.01% 2174
2023
Q2 		$19K Hold
5,251
– – ﹤0.01% 2105
2023
Q1 		$17K Sell
5,251
-4,858
-48% -$19.7K ﹤0.01% 2078
2022
Q4 		$48K Hold
10,109
– – ﹤0.01% 1832
2022
Q3 		$57K Sell
10,109
-4,851
-32% -$37.1K ﹤0.01% 1738
2022
Q2 		$106K Buy
14,960
+4,052
+37% +$27.7K ﹤0.01% 1486
2022
Q1 		$78K Buy
10,908
+2,298
+27% +$15.6K ﹤0.01% 1512
2021
Q4 		$76K Buy
+8,610
New +$134K ﹤0.01% 1545

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lazard Asset Management's AVIR Position: Q4 2023 in Review

Lazard Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2023, closing a stake of 2,298 shares — an estimated $6K sold.

Lazard Asset Management first reported a position in AVIR in Q4 2021 and held it in 8 quarters. The position peaked at $106K in Q2 2022. 108 funds tracked by Wall St. Rank hold AVIR as of Q4 2023.

  • Lazard Asset Management reported no remaining Atea Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Lazard Asset Management sold 2,298 Atea Pharmaceuticals shares in Q4 2023, an estimated $6K.
  • Lazard Asset Management first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • Lazard Asset Management's Atea Pharmaceuticals position peaked at $106K in Q2 2022.
  • 108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2023.

Based on Lazard Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.